Orbapin Tablet 5 mg+40 mg is a dual-action antihypertensive medication containing Amlodipine Besilate 5 mg and Olmesartan Medoxomil 40 mg, specifically formulated for effective management of high blood pressure (hypertension) in adults. Hypertension is a chronic condition that can lead to serious cardiovascular complications, including heart attack, stroke, and kidney disease. By combining two complementary mechanisms of action, Orbapin 5 mg+40 mg provides superior blood pressure control and reduces the risk of cardiovascular events.
Amlodipine Besilate is a calcium channel blocker that relaxes vascular smooth muscles, reducing peripheral resistance and improving blood flow.
Olmesartan Medoxomil is an angiotensin II receptor blocker (ARB) that prevents vasoconstriction and lowers fluid retention, contributing to effective long-term blood pressure control.
This combination is particularly beneficial for patients whose hypertension is not adequately controlled with monotherapy or lower doses of combination therapy.
রেজিস্টার্ড চিকিৎসকের পরামর্শ অনুযায়ী ঔষধ সেবন করুন
Provides effective reduction of systolic and diastolic blood pressure
Dual mechanism ensures enhanced antihypertensive effect
Reduces the risk of cardiovascular complications in hypertensive patients
Convenient once-daily dosing improves adherence
Helps protect heart, kidneys, and blood vessels from hypertensive damage
Suitable for long-term management of essential hypertension
Orbapin Tablet 5 mg+40 mg lowers blood pressure through the combined action of its active ingredients:
Amlodipine Besilate 5 mg:
Inhibits calcium influx in vascular smooth muscle, causing arterial vasodilation.
Lowers peripheral vascular resistance, reducing cardiac workload.
Improves oxygen delivery to cardiac tissues, supporting heart function.
Olmesartan Medoxomil 40 mg:
Blocks angiotensin II type 1 receptors, preventing vasoconstriction.
Reduces aldosterone-mediated sodium and water retention, lowering blood volume.
Supports long-term maintenance of normal blood pressure.
Synergistic Effect:
The combination targets two different pathways in blood pressure regulation, providing more effective and sustained antihypertensive control than either drug alone.
Orbapin Tablet 5 mg+40 mg is indicated for:
Management of essential hypertension in adults
Patients not sufficiently controlled by monotherapy or lower-dose combination therapy
Prevention of cardiovascular complications such as stroke, heart attack, and kidney damage related to high blood pressure
Long-term maintenance of stable blood pressure in patients with elevated cardiovascular risk
Recommended dose: One tablet once daily, orally, as prescribed by a healthcare professional.
Can be taken with or without food, preferably at the same time each day.
Swallow the tablet whole; do not crush or chew.
Monitor blood pressure regularly to assess therapeutic response.
Dose adjustments may be made based on patient response and tolerance.
Not recommended in severe hypotension, pregnancy, or known hypersensitivity to Amlodipine or Olmesartan.
Caution in patients with renal or hepatic impairment; periodic monitoring may be necessary.
Inform the physician of all medications being taken to avoid interactions.
Avoid sudden discontinuation to prevent rebound hypertension.
Monitor kidney function and electrolytes during long-term therapy.
Common side effects include:
Dizziness or lightheadedness
Headache
Flushing
Peripheral edema (swelling of hands, feet, or ankles)
Mild gastrointestinal disturbances
Serious side effects are rare but may include hypotension, kidney dysfunction, or severe allergic reactions. Seek medical attention if severe symptoms occur.
Store below 30°C in a cool, dry place, away from direct sunlight. Keep out of reach of children.
Orbapin Tablet 5 mg+40 mg offers effective and sustained blood pressure control by combining Amlodipine and Olmesartan in a convenient once-daily formulation, reducing cardiovascular risk and promoting long-term vascular and kidney health.
Login Or Registerto submit your questions to seller
No none asked to seller yet